Volume 10, Number 2—February 2004
THEME ISSUE
2004 SARS Edition
Clinical Study
SARS and Pregnancy: A Case Report
Corwin A. Robertson*†
, Sara A. Lowther*‡, Thomas Birch§, Christina Tan†, Faye Sorhage†, Lauren Stockman*‡, L. Clifford McDonald*, Jairam R. Lingappa*, and Eddy Bresnitz†
, Sara A. Lowther*‡, Thomas Birch§, Christina Tan†, Faye Sorhage†, Lauren Stockman*‡, L. Clifford McDonald*, Jairam R. Lingappa*, and Eddy Bresnitz†
Table
Results of SARS-associated coronavirus (SARS-CoV) testing of specimens from case-patient infected while pregnanta,b
| Specimen | SARS-CoV serologic resultsc | SARS-CoV RT-PCR |
|---|---|---|
| Maternal serum |
+ |
ND |
| Maternal whole blood |
– |
ND |
| Maternal nasopharyngeal swab |
ND |
– |
| Maternal rectal swab |
ND |
– |
| Postdelivery placenta d |
– |
– |
| Amniotic fluid |
– |
– |
| Cord blood |
+ |
ND |
| Breast mlk | + | – |
aSARS, severe acute respiratory syndrome; RT-PCR, reverse transcriptase–polymerase chain reaction; ND, not done.
bAll specimens listed were collected 127 days after onset of the case-patient’s illness with the exception of breast milk, which was collected 131 days after illness onset.
cSerologic analysis included enzyme immunoassay and indirect immunofluorescence assay.
dPostdelivery placenta also underwent immunohistochemical (IHC) staining; there was no IHC evidence of SARS-CoV.
Page created: January 27, 2011
Page updated: January 27, 2011
Page reviewed: January 27, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.